Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Anti-HLA-A2-MAGE-A4/Anti-CD3 Bispecific Antibody RO7444973

A bispecific T-cell engaging antibody directed against both the tumor-associated antigen (TAA) human leukocyte antigen (HLA)-A2-restricted, melanoma-associated antigen A4 (MAGE-A4) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A2-MAGE-A4/Anti-CD3 bispecific antibody RO7444973 simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HLA-A2 MAGE-A4 on MAGE-A4-expressing tumor cells. This activates and redirects CTLs to MAGE-A4-expressing tumor cells, which results in the CTL-mediated cell death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HLA-A2-MAGE-A4/anti-CD3 bispecific antibody RG6129
anti-HLA-A2-MAGE-A4/CD3 bispecific antibody RO7444973
HLA-A2-MAGE-A4 x CD3 bispecific antibody RO7444973
Code name:RG 6129
RG-6129
RG6129
RO 7444973
RO-7444973
RO7444973
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search